STAT+: Pharma’s ambitious new antibiotic venture fund makes its first investments

“This should put the stamp down that we’re up and running and open for business," said Henry Skinner, who runs the AMR Action Fund.

One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.

The fund is providing an undisclosed portion of its $1 billion in initial backing — much of which comes from several of the world’s largest drug manufacturers — toward Venatorx Pharmaceuticals and Adaptive Phage Therapeutics. The two privately held companies are taking a different approach toward developing therapies that can fight drug-resistant infections.

Continue to STAT+ to read the full story…